13,155 Shares in BridgeBio Pharma, Inc. (NASDAQ:BBIO) Bought by Cibc World Markets Corp

Cibc World Markets Corp purchased a new stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 13,155 shares of the company’s stock, valued at approximately $361,000.

A number of other large investors have also added to or reduced their stakes in the company. Steward Partners Investment Advisory LLC raised its stake in shares of BridgeBio Pharma by 85.8% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 1,022 shares of the company’s stock valued at $28,000 after acquiring an additional 472 shares during the last quarter. Advisors Asset Management Inc. raised its position in BridgeBio Pharma by 56.1% during the 3rd quarter. Advisors Asset Management Inc. now owns 4,576 shares of the company’s stock valued at $117,000 after purchasing an additional 1,645 shares during the last quarter. Avanza Fonder AB bought a new position in BridgeBio Pharma during the 4th quarter valued at approximately $181,000. First Bank & Trust purchased a new stake in BridgeBio Pharma in the 4th quarter worth approximately $205,000. Finally, Moss Adams Wealth Advisors LLC bought a new stake in shares of BridgeBio Pharma in the 4th quarter worth approximately $208,000. Institutional investors own 99.85% of the company’s stock.

Analyst Upgrades and Downgrades

BBIO has been the subject of a number of recent analyst reports. Citigroup upped their target price on BridgeBio Pharma from $45.00 to $49.00 and gave the company a “buy” rating in a report on Friday, February 21st. Evercore ISI raised their target price on shares of BridgeBio Pharma from $45.00 to $50.00 and gave the stock an “outperform” rating in a research report on Monday, December 23rd. Bank of America lifted their target price on shares of BridgeBio Pharma from $42.00 to $45.00 and gave the company a “buy” rating in a research note on Monday, November 25th. Scotiabank increased their price target on shares of BridgeBio Pharma from $49.00 to $52.00 and gave the stock a “sector outperform” rating in a research note on Friday, February 21st. Finally, HC Wainwright reaffirmed a “buy” rating and set a $49.00 price objective on shares of BridgeBio Pharma in a research report on Thursday, February 13th. One analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $52.90.

Insider Transactions at BridgeBio Pharma

In other BridgeBio Pharma news, CFO Brian C. Stephenson sold 68,000 shares of the business’s stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $36.29, for a total value of $2,467,720.00. Following the completion of the transaction, the chief financial officer now owns 93,758 shares of the company’s stock, valued at approximately $3,402,477.82. The trade was a 42.04 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Genetic Disorder L.P. Kkr sold 6,000,000 shares of the firm’s stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $32.96, for a total transaction of $197,760,000.00. Following the sale, the insider now directly owns 19,260,971 shares in the company, valued at approximately $634,841,604.16. The trade was a 23.75 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 9,579,739 shares of company stock worth $323,171,901. Corporate insiders own 24.66% of the company’s stock.

BridgeBio Pharma Trading Up 7.0 %

Shares of NASDAQ:BBIO opened at $37.22 on Tuesday. The stock has a fifty day simple moving average of $34.15 and a two-hundred day simple moving average of $29.12. BridgeBio Pharma, Inc. has a 12-month low of $21.62 and a 12-month high of $39.47. The stock has a market capitalization of $7.08 billion, a price-to-earnings ratio of -13.06 and a beta of 1.07.

BridgeBio Pharma (NASDAQ:BBIO) last posted its quarterly earnings results on Thursday, February 20th. The company reported ($1.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.09) by ($0.22). The firm had revenue of $5.88 million during the quarter, compared to analysts’ expectations of $4.04 million. As a group, equities research analysts predict that BridgeBio Pharma, Inc. will post -3.67 EPS for the current year.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.